



# Accessing Escalated Risankizumab in Crohn's Disease: How Long Does it Take?

Patrick Nichols, PharmD<sup>1</sup>, Montana Gunter, PharmD Candidate<sup>2</sup>, Autumn D. Zuckerman PharmD, BCPS, CSP<sup>1</sup> Nicolas Gargurevich, MS<sup>3</sup>, Robin Dalal, MD<sup>4</sup>

<sup>1</sup>Vanderbilt Specialty Pharmacy, Vanderbilt Health; <sup>2</sup>Belmont University College of Pharmacy & Health Sciences, <sup>3</sup>Department of Biostatistics, Vanderbilt University Medical Center; <sup>4</sup>Vanderbilt Health

### Background

- Risankizumab (RZB) can be administered more frequently than the FDA-approved 360mg or 180mg every 8 weeks for Crohn's Disease (CD).
- Literature describing RZB escalated dosing access is limited.

### Purpose

This study aimed to describe the approval process required for RZB dose escalation, including quantifying the time to approval and analyzing patient and insurance characteristics associated with approval.

### Methods

Retrospective cohort analysis performed at Vanderbilt Health System Inflammatory Bowel Disease Clinic with an integrated health system specialty pharmacy (HSSP)

**Design**

Patients were included if they received at least one escalated dose of RZB between June 2022 and April 2024


**Population**

Time to access escalated dose from referral to approval

Steps required to obtain access

**Outcome Measures**

Figure 1. Escalated Dose Access Process



# CONCLUSION

- Accessing escalated RZB dosing took a median of 2 weeks, but often up to a month.
- The approval pathway frequently required steps beyond a PA.
- The delays and additional steps highlight the barriers faced by patients who require dose escalation.

## Results

Figure 2. Patient Demographics




Figure 3. Method of Access




Figure 4. Time to Approval by Step




Figure 5. Time to Approval by Insurance




Figure 6. Time to Approval by Number of Previous Therapies Tried

